FANCA and Friedreich ataxia: These results demonstrate that the targeting of therapeutic FANCA donors in the AAVS1 site of FA‐A LCLs mediates the correction of two characteristic phenotypes of FA cells, their hypersensitivity to DNA cross‐linking drugs and the spontaneous production of ROS.